About this trial
MK-7684A is an experimental treatment. It is an immunotherapy. This means it works by stimulating the body’s own immune system to fight the cancer. It is a combination of 2 drugs: MK 7684 and pembrolizumab (pembro).
MK-7684 is an experimental drug. It is also called vibostolimab. It has not been approved for sale.
Pembro has been approved by certain health authorities for treating various cancers.
Atezolizumab is also an immunotherapy. It has been approved by certain health authorities for treating various cancers, including SCLC.
Patient Profile
This study is for patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer Who meet the following criteria:
– ECOG Performance status of 0-1 (this is a scale measuring your ability to carry out normal activities including your ability to care for yourself, daily and physical activities)
– No active brain metastases requiring treatment
– No autoimmune or neurologic paraneoplastic syndromes
– No pneumonitis or interstitial lung disease
Where’s this trial being run?
Beaumont Hospital and St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK7684A-008 |
|---|---|
| Number: | 22-06 |
| Full Title: | Phase III Study of MK-7684A with |
| Principal Investigator: | Dr Dearbhaile Collins |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | MSD |
| Recruitment Started: |
Global: Yes Ireland: Yes |
| Global Recruitment Target: | 450 |
|---|---|
| Ireland Recruitment Target: | 6+ |